Decentralized Clinical Trials in the Development of Drugs and Biological Products
Open Access
- 2 February 2024
- journal article
- research article
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 59 (6) , 1191-1193
Abstract
Decentralized clinical trials (DCTs) are trials where some or all of the trial-related activities occur at locations other than traditional clinical trial sites. FDA supports decentralization to improve participation in clinical trials. While there are benefits of DCTs, including convenience for participants, sponsors and investigators should be aware of potential challenges such as coordination of trial activities at locations other than traditional trial sites and supervision of delegated trial-activities performed remotely. Appropriate training, oversight, and up-front risk assessment and management will be key to implementing a DCT successfully.Keywords
This publication has 3 references indexed in Scilit:
- Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19JAMA, 2020
- At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical TrialsThe Oncologist, 2018
- Web-based trial to evaluate the efficacy and safety of tolterodine ER 4mg in participants with overactive bladder: REMOTE trialContemporary Clinical Trials, 2014